Stereoselective Voltammetric Biosensor for Myo-Inositol and D-Chiro-Inositol Recognition

被引:2
|
作者
Tortolini, Cristina [1 ]
Gigli, Valeria [1 ]
Rizzo, Flavio [1 ]
Lenzi, Andrea [1 ]
Bizzarri, Mariano [1 ]
Angeloni, Antonio [1 ]
Antiochia, Riccarda [2 ]
机构
[1] Sapienza Univ Rome, Dept Expt Med, Viale Regina Elena 324, I-00161 Rome, Italy
[2] Sapienza Univ Rome, Dept Chem & Drug Technol, Piazzale Aldo Moro 5, I-00185 Rome, Italy
关键词
myo-inositol; D-chiro-inositol; biosensor; stereoselective recognition; voltammetric detection; MWCNTs; ENANTIOMERIC SEPARATION; ENANTIOSELECTIVE RECOGNITION; CAPILLARY-ELECTROPHORESIS; ELECTROCHEMICAL SENSOR; LIQUID-CHROMATOGRAPHY; INSULIN-RESISTANCE; DRUGS; MEDIATORS; DISEASE; BINDING;
D O I
10.3390/s23229211
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
This paper describes the development of a simple voltammetric biosensor for the stereoselective discrimination of myo-inositol (myo-Ins) and D-chiro-inositol (D-chiro-Ins) by means of bovine serum albumin (BSA) adsorption onto a multi-walled carbon nanotube (MWCNT) graphite screen-printed electrode (MWCNT-GSPE), previously functionalized by the electropolymerization of methylene blue (MB). After a morphological characterization, the enantioselective biosensor platform was electrochemically characterized after each modification step by differential pulse voltammetry (DPV) and electrochemical impedance spectroscopy (EIS). The results show that the binding affinity between myo-Ins and BSA was higher than that between D-chiro-Ins and BSA, confirming the different interactions exhibited by the novel BSA/MB/MWCNT/GSPE platform towards the two diastereoisomers. The biosensor showed a linear response towards both stereoisomers in the range of 2-100 mu M, with LODs of 0.5 and 1 mu M for myo-Ins and D-chiro-Ins, respectively. Moreover, a stereoselectivity coefficient alpha of 1.6 was found, with association constants of 0.90 and 0.79, for the two stereoisomers, respectively. Lastly, the proposed biosensor allowed for the determination of the stereoisomeric composition of myo-/D-chiro-Ins mixtures in commercial pharmaceutical preparations, and thus, it is expected to be successfully applied in the chiral analysis of pharmaceuticals and illicit drugs of forensic interest.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Effects of dietary myo-inositol, D-chiro-inositol and L-chiro-inositol on hepatic lipids with reference to the hepatic myo-inositol status in rats fed on 1,1,1-trichloro-2,2-bis (p-chlorophenyl) ethane
    Okazaki, Yukako
    Setoguchi, Tomoyasu
    Katayama, Tetsuyuki
    BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2006, 70 (11) : 2766 - 2770
  • [42] Results from the International Consensus Conference on Myo-inositol and D-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS
    Facchinetti, Fabio
    Bizzarri, Mariano
    Benvenga, Salvatore
    D'Anna, Rosario
    Lanzone, Antonio
    Soulage, Christophe
    Di Renzo, Gian Carlo
    Hod, Moshe
    Cavalli, Pietro
    Chiu, Tony T.
    Kamenov, Zdravko A.
    Bevilacqua, Arturo
    Carlomagno, Gianfranco
    Gerli, Sandro
    Oliva, Mario Montanino
    Devroey, Paul
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2015, 195 : 72 - 76
  • [43] Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study
    Jacopo Troisi
    Claudia Cinque
    Luigi Giugliano
    Steven Symes
    Sean Richards
    David Adair
    Pierpaolo Cavallo
    Laura Sarno
    Giovanni Scala
    Maria Caiazza
    Maurizio Guida
    Journal of Ovarian Research, 12
  • [44] The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios
    Nordio, M.
    Basciani, S.
    Camajani, E.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (12) : 5512 - 5521
  • [45] Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients
    Monastra, Giovanni
    Unfer, Vittorio
    Harrath, Abdel Halim
    Bizzarri, Mariano
    GYNECOLOGICAL ENDOCRINOLOGY, 2017, 33 (01) : 1 - 9
  • [46] Metabolomic change due to combined treatment with myo-inositol, D-chiro-inositol and glucomannan in polycystic ovarian syndrome patients: a pilot study
    Troisi, Jacopo
    Cinque, Claudia
    Giugliano, Luigi
    Symes, Steven
    Richards, Sean
    Adair, David
    Cavallo, Pierpaolo
    Sarno, Laura
    Scala, Giovanni
    Caiazza, Maria
    Guida, Maurizio
    JOURNAL OF OVARIAN RESEARCH, 2019, 12 (1)
  • [47] The combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients
    Minozzi, M.
    Nordio, M.
    Pajalich, R.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2013, 17 (04) : 537 - 540
  • [48] Strategy to improve the female fertility in the general gynecologist's office: use of a nutritional supplement based on myo-inositol/D-chiro-inositol and antioxidants
    Mendoza, Nicolas
    Losa, Fernando
    Palacios, Santiago
    GYNECOLOGICAL ENDOCRINOLOGY, 2022, 38 (04) : 275 - 278
  • [49] The D-chiro-inositol paradox in the ovary
    Carlomagno, Gianfranco
    Unfer, Vittorio
    Roseff, Scott
    FERTILITY AND STERILITY, 2011, 95 (08) : 2515 - 2516
  • [50] Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial
    Mendoza, Nicolas
    Paz Diaz-Ropero, Maria
    Aragon, Miguel
    Maldonado, Vicente
    Llaneza, Placido
    Lorente, Juan
    Mendoza-Tesarik, Raquel
    Maldonado-Lobon, Jose
    Olivares, Monica
    Fonolla, Juristo
    GYNECOLOGICAL ENDOCRINOLOGY, 2019, 35 (08) : 695 - 700